# Clinical Study of CN128 in Thalassemia Patients

> **NCT03673085** · PHASE1 · COMPLETED · sponsor: **Hangzhou Zede Pharma-Tech Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Thalassemia

## Interventions

- **DRUG:** CN128
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT03673085
- **Lead sponsor:** Hangzhou Zede Pharma-Tech Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-05
- **Primary completion:** 2018-10-16
- **Final completion:** 2019-12-17
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03673085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03673085, "Clinical Study of CN128 in Thalassemia Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03673085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*